OTHER SUPPORT
LERNMARK,
ÅKE
UNIVERSITY OF WASHINGTON
ACTIVE
PO1-AI42380-09 (Lernmark) 08/01/05-01/31/10
1.2 calendar, Project 1
NIH/NIAID $825,912 0.60 calendar, Core A
Genetic control of BB rat
autoimmunity
This
Program Project aims to uncover genes which control the development of
spontaneous organ-specific autoimmune disease in the rat. Lymphopenia (lyp), insulitis and
thyroiditis phenotypes are analyzed and genetic factors positionally cloned in
congenic BB and Fischer rats.
1UO1 DK063861-04 (Lernmark) 01/1/03-12/30/07
2.4 calendar
NIH/NIDDK $722,838
TEDDY - Diabetes Prediction
in Skåne (DiPiS)
This study is a consortium of six clinical centers in the
TEDDY (Triggers and Environmental Determinants of Diabetes in the Young) study.
DiPiS will screen 10,000 children per year for high risk HLA and other T1DM
genetic factors.
DK17047-20 (Program Director: Palmer, Molecular and Genetics
Core Director: Lernmark)
NIH/NIDDK 12/01/02-11/30/07 1.2
calendar (donated)
Diabetes Endocrinology Research Center (DERC) $84,362
The Molecular and
Genetics Core is providing: (a) consultation and training, (b) preparation and
dissemination of molecular biology reagents, and (c) service work to carry out
specific molecular biology projects or genetic mapping.
7-03-MN-30
(Lernmark) 07/01/03-06/30/07 0 calendar
American Diabetes
Association $45,000
Ian5 Gene Induction of Type 1 Diabetes,
Mentor Based Fellowship
This
grant is to support a fellow to work on identifying how this mutation defect,
present from birth, initiated T-cell mediated ß-cell destruction at 50-80 days
of age in the lymphopenic diabetes-prone (DP) BB rat.
1-04-TLG-06
(Lernmark) 01/01/04-12/31/06
0.60 calendar
American Diabetes Association $100,000
Gregg
Award
The
objective is to determine the impact of cord blood autoantibodies on type 1
diabetes development in children with high risk HLA. The long term goal is to develop measures of tolerance induction
that can be used to prevent type 1 diabetes.
P30DK47754 (Osborne) 01/01/05-12/31/06 0.60 calendar
NIH/NIAID, Pilot and Feasibility
Award $200,000
Lentivirus-mediated
transfer of IAN5 to treat type 1 diabetic rats
The objective of this research is to
investigate lentivirus-mediated gene therapy to treat spontaneously diabetic BB
rats, a well characterized model of T1DM. We propose to use lentivirus vectors
to transduce bone marrow stem cells to express wild type IAN5 cDNA under the
control of a thymocyte specific promoter. These studies will provide necessary
pre-clinical data of lentivirus-mediated gene therapy of diabetic rats that may
lead to application to patients.
PO1 DK053004 (Lernmark) 07/15/05-06/30/08
1.8 calendar, Project 2
NIH/NIDDK $711,341 0.60 calendar, Core A
Immunogenetics of Human Diabetes
Determine the mechanisms of type 1
diabetes development in non-progressors and progressors to disease. Analyze the interaction between T and B
lymphocytes as well as the autoimmune response in patients with type 2 diabetes
as well as at children at risk for developing diabetes.
4-2001-433 (Gerald
Nepom, Center Director; Lernmark P.I. on subcontract)
3/1/03-9/30/06 0.60
calendar
Juvenile Diabetes Research Foundation $72,727
JDRF Center for
Translational Research at the Benaroya Research Institute at Virginia Mason
Profiling of islet
antigen specific immunity in IDDM.
2 R01
DK026190-19A2 (Lernmark) 04/01/06-02/28/11
1.8 calendar
NIH/NIDDK $205,000
Islet
Cell Membrane Antibodies in Diabetes
The long-term objective of this
continued application is to identify the role of beta cell autoantigens in
insulin-dependent diabetes mellitus.
Epitope mapping of GAD65 antibodies tested to predict disease.
PENDING
None.
OVERLAP
None.